Frontier Biotechnologies

About

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.